Crossmark Global Holdings Inc. Sells 669 Shares of Elevance Health, Inc. (NYSE:ELV)

Crossmark Global Holdings Inc. lowered its stake in Elevance Health, Inc. (NYSE:ELV) by 3.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 21,815 shares of the company’s stock after selling 669 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Elevance Health were worth $8,048,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in ELV. Raelipskie Partnership bought a new stake in Elevance Health during the 3rd quarter valued at $26,000. PSI Advisors LLC purchased a new position in shares of Elevance Health in the third quarter valued at about $27,000. Eastern Bank bought a new position in shares of Elevance Health during the third quarter valued at about $31,000. Dunhill Financial LLC boosted its holdings in shares of Elevance Health by 57.8% during the third quarter. Dunhill Financial LLC now owns 71 shares of the company’s stock worth $37,000 after purchasing an additional 26 shares during the period. Finally, Peterson Financial Group Inc. bought a new stake in shares of Elevance Health in the third quarter worth about $44,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Up 1.1 %

ELV stock opened at $389.45 on Wednesday. The business has a 50 day moving average of $387.20 and a 200 day moving average of $465.15. The firm has a market cap of $90.32 billion, a PE ratio of 14.20, a price-to-earnings-growth ratio of 1.09 and a beta of 0.84. Elevance Health, Inc. has a twelve month low of $362.21 and a twelve month high of $567.26. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.56.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on ELV shares. Wells Fargo & Company dropped their price objective on Elevance Health from $593.00 to $495.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Mizuho dropped their price target on Elevance Health from $585.00 to $505.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Raymond James set a $485.00 price objective on shares of Elevance Health in a research report on Friday, October 18th. TD Cowen dropped their target price on shares of Elevance Health from $589.00 to $484.00 and set a “buy” rating for the company in a research report on Monday, October 21st. Finally, Stephens reiterated an “underperform” rating on shares of Elevance Health in a research report on Friday, October 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $536.53.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.